Eisele Jeffrey has filed 24 insider transactions across 1 company since January 2023.
Most recent transaction: a sale of 278 shares of Apellis Pharmaceuticals, Inc. ($APLS) on January 29, 2025.
Activity breakdown: 0 open-market purchases and 15 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 29, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 278 | $29.52 | 55,312.0000 | 123,905,000 | 0.50% | 0.00% |
| Jan. 22, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 1291 | $30.43 | 55,590.0000 | 123,905,000 | 2.27% | 0.00% |
| Jan. 13, 2025 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 264 | $28.70 | 56,881.0000 | 123,905,000 | 0.46% | 0.00% |
| Dec. 23, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 63 | $33.09 | 57,145.0000 | 124,234,000 | 0.11% | 0.00% |
| Jan. 29, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 279 | $64.14 | 58,179.0000 | 118,678,000 | 0.48% | 0.00% |
| Jan. 30, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 971 | $65.53 | 57,208.0000 | 118,678,000 | 1.67% | 0.00% |
| Jan. 23, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 7378 | $63.69 | 58,458.0000 | 118,678,000 | 11.21% | 0.01% |
| Jan. 22, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 1607 | $65.00 | 65,836.0000 | 118,678,000 | 2.38% | 0.00% |
| Jan. 17, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 5207 | $65.58 | 67,443.0000 | 118,678,000 | 7.17% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | A | Common Stock | 19508 | $0.00 | 73,088.0000 | 118,678,000 | 36.41% | 0.02% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 438 | $66.81 | 72,650.0000 | 118,678,000 | 0.60% | 0.00% |
| Jan. 16, 2024 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | A | Stock Option (Right to Buy) | 28367 | $66.30 | 28,367.0000 | 118,678,000 | 9999.99% | 0.02% |
| Dec. 26, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 68 | $57.86 | 53,815.0000 | 106,114,000 | 0.13% | 0.00% |
| Dec. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 235 | $60.23 | 53,580.0000 | 106,114,000 | 0.44% | 0.00% |
| Feb. 23, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 1646 | $68.76 | 53,883.0000 | 106,114,000 | 2.96% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | A | Common Stock | 9886 | $0.00 | 56,354.0000 | 106,114,000 | 21.27% | 0.01% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | F | Common Stock | 825 | $58.50 | 55,529.0000 | 106,114,000 | 1.46% | 0.00% |
| Feb. 21, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | A | Stock Option (Right to Buy) | 14023 | $0.00 | 14,023.0000 | 106,114,000 | 9999.99% | 0.01% |
| Jan. 30, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 883 | $52.76 | 46,468.0000 | 106,114,000 | 1.86% | 0.00% |
| Jan. 27, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | F | Common Stock | 367 | $52.77 | 47,351.0000 | 106,114,000 | 0.77% | 0.00% |
| Jan. 23, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | S | Common Stock | 4479 | $51.58 | 47,718.0000 | 106,114,000 | 8.58% | 0.00% |
| Jan. 20, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | F | Common Stock | 2033 | $52.05 | 52,197.0000 | 106,114,000 | 3.75% | 0.00% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | A | Common Stock | 22580 | $0.00 | 54,230.0000 | 106,114,000 | 71.34% | 0.02% |
| Jan. 12, 2023 | Apellis Pharmaceuticals, Inc. | $APLS | Eisele Jeffrey | Chief Development Officer | A | Stock Option (Right to Buy) | 35472 | $52.66 | 35,472.0000 | 106,114,000 | 9999.99% | 0.03% |